Dimas G, Iliadis F, Grekas D
First Internal Medicine Propaedeutic Department, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Greece.
Hippokratia. 2013 Oct;17(4):292-7.
Matrix metalloproteinases (MMPs) are important enzymes of extracellular matrix (ECM) degradation for creating the cellular environments required during development and morphogenesis. MMPs, collectively called matrixins, regulate also the biological activity of non matrix substrates such as cytokines, chemokines, receptors, growth factors and cell adhesion molecules. Enzymatic activity is regulated at multiple levels. Endogenous specific inhibitors of metalloproteinases (TIMPs) participate in controlling the local activities of MMPs in tissues. The pathological effects of MMPs and TIMPs are involved in cardiovascular disease (CVD) processes, including atherosclerosis and in a number of renal pathophysiologic alterations, both acute and chronic, linking them to acute kidney injury, glomerulosclerosis and tubulointerstitial fibrosis. This review presents an overview of the place of MMPs in atherosclerosis, proteinuria and kidney disease as a subject of considerable interest, given the differentiated and ambiguous role of MMPs in the progression of these diseases.
基质金属蛋白酶(MMPs)是细胞外基质(ECM)降解的重要酶类,在发育和形态发生过程中创造所需的细胞环境。MMPs统称为基质溶解素,还调节非基质底物如细胞因子、趋化因子、受体、生长因子和细胞粘附分子的生物活性。酶活性在多个水平受到调节。金属蛋白酶的内源性特异性抑制剂(TIMPs)参与控制组织中MMPs的局部活性。MMPs和TIMPs的病理作用涉及心血管疾病(CVD)过程,包括动脉粥样硬化以及一些急慢性肾脏病理生理改变,将它们与急性肾损伤、肾小球硬化和肾小管间质纤维化联系起来。鉴于MMPs在这些疾病进展中作用的差异和模糊性,本综述概述了MMPs在动脉粥样硬化、蛋白尿和肾脏疾病中的地位,这是一个备受关注的主题。